Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  recombinant interferon alfa-2b
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E1609, NCI-2011-02649, CDR0000692568, ECOG-E1609, NCT01274338
Ipilimumab, Combination Chemotherapy, and Biological Therapy in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2011-0073, NCI-2011-02768, NCT01409174
Ipilimumab with or without High-Dose Recombinant Interferon Alfa-2b in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3611, NCI-2012-01932, CDR0000741878, ECOG-E3611, NCT01708941
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Ipilimumab and PEG-Proline-Interferon Alpha-2b in Treating Patients with Locally/Regionally Advanced/ Recurrent Melanoma.
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 11-063, NCI-2015-00168, 11-063, NCT01608594
Vaccine Therapy With or Without Recombinant Interferon Alfa-2b in Treating Patients With Recurrent Stage III-IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-021, NCI-2013-00388, UPCI 09-021, NCT01622933
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-107, NCI-2013-01876, PRO13040314, NCT01943422
A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29322, NCI-2014-02163, 2014-000812-33, NCT02174172
Recombinant Interferon Alfa-2b or PEG-Interferon Alfa-2b in Treating Patients With Melanoma Undergoing Sentinel Lymph Node Biopsy
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 08-067, NCI-2011-02485, NCT00871533
Start Over